ArticleBMC cancer2026
Role of SFTPD/miR-335-5p/lnc-HNRNPUL2 axis in colorectal cancer: in silico characterization and clinical validation.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe lnc-RNA, miRNA, and mRNA networks have been extensively studied for cancer regulation. Furthermore, ceRNA network analysis has proved as an effective candidate for identifying potential diagnostic biomarkers in a variety of cancers. In this study, we described a novel axis of serum Surfactant protein D (SFTPD)/miR-335-5p/lnc-HNRNPUL2 proposed by bioinformatics analysis and validated in a pilot human study of CRC versus control & in vitro assay to explore its role in the CRC pathogenesis.
methodsReal-time PCR and ELISA were used to validate the expression of this axis panel in serum samples from 81 CRC patients, 41 patients with benign tumors, and 30 healthy controls. Its expression was also confirmed in the CRC cell line HT29.
resultsLnc-HNRNPUL2 and TGF-β expression levels were significantly upregulted in the sera of CRC patients compared to controls, along with a concurrent decrease in the expression of miR-335-5p and SFTPD mRNA in the CRC group relative to both benign and healthy control groups Interestingly, lnc-HNRNPUL2 and hsa-miR-335-5p had significant predictive values for CRC diagnosis due to their high sensitivities and specificities (AUC = 0.901 and 0.877, respectively). In addition, we silenced lnc-HNRNPUL2 in HT29 cells, which resulted in a significant decrease in cell count and viability, as well as a restoration of normal panel expression.
conclusionTogether, these findings point to an oncogenic role for lnc-HNRNPUL2 in CRC, which acts via miR-335-5p suppression, followed by a decrease in SFTPD mRNA that is involved in immune surveillance against several cancers. The SFTPD/miR-335-5p/lnc-HNRNPUL2 axis shows high diagnostic accuracy for CRC detection. Low miR-335-5p expression was significantly associated with metastasis in Cox regression analysis, but longer follow-up is needed to establish prognostic value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.